Phase I Clinical Trial of DA-6886 in Healthy Male Subjects

A Phase I, Dose Block-randomized, Double-blind, Placebo-controlled, Single/Multiple Dosing, Dose Escalation Clinical Trial With Open-labelled Food Effect Study of Single Dose to Investigate the Safety, Tolerability and Pharmacokinetics of DA-6886 After Oral Administration in Healthy Male Subjects

DA-6886_IBS_I is a phase I, dose block-randomized, double-blind, placebo-controlled, single/multiple dosing, dose escalation clinical trial with open-labelled food effect study of single dose to investigate the safety, tolerability and pharmacokinetics of DA-6886 after oral administration in healthy male subjects.

Inclusion Criteria:

• 20 ~ 45 years old
• 27kg/m2 ≥ BMI ≥ 20kg/m2
• Healthy Male
• Informed consent

Exclusion Criteria:

• Clinically significant medical history
• smokers
• Clinically significant hypersensitivity of Drugs
• Clinically significant cutaneous disorder
• QTcB > 450msec
• have a history of drug abuse or show positive for drug abuse or cotinine at urine screening